HIKMA, A CONVINCINGLY DIFFERENT PHARMA (ADD; 12% UPSIDE)
23/12/20 -"Since our last endorsement in April 2020, it has been a seesaw ride for the generic drugs manufacturer, Hikma (Add, UK). While the reiteration of its FY20 targets (in May), at a time when peers were ..."
Pages
51
Language
English
Published on
23/12/20
You may also be interested by these reports :
11/03/26
BioNTech’s full-year results revealed sales surpassing expectations, although the operating loss was higher than anticipated. The 2026 sales guidance ...
11/03/26
While we acknowledge the upcoming HIV patent expiries (c.17% of sales) starting 2027-28, we remain encouraged by GSK’s execution ability as it ...
06/03/26
We have incorporated the 2025 reported figures and added a new forecast year (2028) to our model. Consequently, we have reduced the out-year sales ...
05/03/26
The Q4 results fell somewhat short of expectations, as Life Science and Healthcare witnessed decent growth, whereas the quarter was tough for ...